Search
for

    GlossaryIC50

    concentration needed to inhibit a biological process by 50%

    IC50, or Half Maximal Inhibitory Concentration, is a measure used in pharmacology to indicate how much of a substance (like a drug or inhibitor) is needed to inhibit a biological process or the activity of a target (such as an enzyme or cell receptor) by 50%. This value helps researchers understand the potency of a compound, with a lower IC50 indicating a more potent inhibitor.

    Related Terms

    Learn

    1 / 1 results

      learn Pyrilutamide

      highly targeted anti-androgen that might have minimal systemic effects
      [object Object]

    Research

    5 / 126 results

    Community Join

    5 / 12 results

      community Pyrilutamide ,the molecule’s true nature

      by Typical-Promise-3001 in Research  302 upvotes 5 months ago
      Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

      community KX-826 Pyrilutamide1% coming soon

      by _thebluehue_ in Update  152 upvotes 5 months ago
      KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.
      [object Object]
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      by nkrata in Research  330 upvotes 5 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.